Renalguard system: A dedicated device to prevent contrast-induced acute kidney injury

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 643-644

  Briguori, Carlo ^a,b  

^a Clinica Mediterranea   (Italy)

^b Clinica Mediterranea   (Italy)

Author keywords

Complication; Contrast media; Kidney; Prevention

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; CYSTATIN C; FUROSEMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; APOPTOSIS; COMPARATIVE EFFECTIVENESS; CONTRAST INDUCED NEPHROPATHY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEVICE SAFETY; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPOVOLEMIA; KIDNEY CELL; LUNG EDEMA; NOTE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK REDUCTION; SIGNAL TRANSDUCTION; URINE FLOW RATE; URINE VOLUME; UROLOGICAL THERAPEUTIC DEVICE;

COMPLICATION; CONTRAST MEDIA; KIDNEY; PREVENTION;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINATION;

EID: 84885320287     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.12.069     Document Type: Note

References (18)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51: 1419-28.
2. Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98:14K-20K.
3. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 2006:S8-S10.
4. Romano G, Briguori C, Quintavalle C, et al. Contrast agents and renal cell apoptosis. Eur Heart J 2008;29:2569-76.
5. Quintavalle C, Brenca M, De Micco F, et al. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death Dis 2011;2:e155.
6. Lei K, Davis RJ. Jnk phosphorylation of bim-related members of the bcl2 family induces bax-dependent apoptosis. Proc Natl Acad Sci U S A 2003;100:2432-7.
7. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 2006:S51-3.
8. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
9. Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006;21:2120-6.
10. Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with ckd undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis 2009;54:602-9.
11. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of radiocontrast induced nephropathy clinical evaluation. J Am Coll Cardiol 1999;33:403-11.
12. Dorval JF, Dixon SR, Zelman RB, Davidson CJ, Rudko R, Resnic FS. Feasibility study of the RenalGuard™ balanced hydration system: a novel strategy for the prevention of contrast-induced nephropathy in high risk patients. Intern J Cardiol 2013;166:482-6.
13. Briguori C, Visconti G, Focaccio A, et al. Renal insufficiency after contrast media administration trial II (REMEDIAL II): Renalguard system in high-risk patients for contrast-induced acute kidney injury. Circulation 2011;124:1260-9.
14. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-40.
15. Romano G, Briguori C, Quintavalle C, et al. Contrast agents and renal cell apoptosis. Eur Hearth J 2008;29:2569-76.
16. Briguori C, Quintavalle C, De Micco F, Condorelli G. Nephrotoxicity of contrast media and protective effects of acetylcysteine. Arch Toxicol 2010;85:165-73.
17. Investigators ACT. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011;124:1250-9.
18. Marenzi G, Assanelli E, Marana I, et al. Furosemide-induced diuresis with matched hydration compared to standard hydration for contrast-induced nephropathy prevention: preliminary results of the MYTHOS trial. J Am Coll Cardiol Interv (in press).